Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06938815 · ClinicalTrials.gov registry record · NA
A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color
A NA study of Post-inflammatory Hyperpigmentation, sponsored by Narrows Institute for Biomedical Research.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06938815: Completed NA study of Post-inflammatory Hyperpigmentation, sponsored by Narrows Institute for Biomedical Research.
NCT06938815 is a NA study of Post-inflammatory Hyperpigmentation that has completed, run by Narrows Institute for Biomedical Research. The registered enrollment target is 10 participants, below the 24-participant average among 3 other Post-inflammatory Hyperpigmentation trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06938815, a NA study of Post-inflammatory Hyperpigmentation, has completed, sponsored by Narrows Institute for Biomedical Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, prospective, non-blinded, non-randomized 12 week clinical study to evaluate the efficacy of a SkinCeuticals comprehensive skin care regimen in the reduction of post inflammatory hyperpigmentation (PIH) in skin of color patients. The comprehensive regimen features the Pigment Balancing Peel which combines glycolic acid, lactic acid, kojic acid, vitamin C, and emblica into a treatment that may improve skin discoloration. Participants will supplement the Pigment Balancing Peel with a 11 week regimen that includes the Hydrating B5 Gel, Discoloration Defense, LHA Cleansing Gel, and Brightening UV Defense sunscreen.
Primary Outcome
Change in the patient satisfaction with their physical appearance following use of SkinCeuticals regimen to improve post inflammatory hyperpigmentation, using the FACE-Q Satisfaction (scores range from 0 (lowest) to 100 (highest)), at week 12 compared to baseline.
Conditions Studied
Interventions
- OTHER Pigment Balancing Peel
- OTHER Discoloration Defense Serum
- OTHER LHA Cleansing Gel
- OTHER Hydrating B5 Gel
- OTHER Daily Brightening Sunscreen
Study Locations (1)
New York
- New York Harbor VA Brooklyn Campus - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2025-07-20 |
| Phase | NA |
What the finished NCT06938815 record still lists
NCT06938815 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 24-participant average among 3 other Post-inflammatory Hyperpigmentation trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Post-inflammatory Hyperpigmentation appearing as the primary indexed condition, and to 5 interventions - of which Pigment Balancing Peel is the first listed.
NCT06938815 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06938815 about?
NCT06938815 is a clinical study titled "A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color". This is a single-center, prospective, non-blinded, non-randomized 12 week clinical study to evaluate the efficacy of a SkinCeuticals comprehensive skin care regimen in the reduction of post inflammatory hyperpigmentation (PIH) in skin of color patients. The comprehensive regimen features the Pigment...
What is the current status of trial NCT06938815?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2025-02-28. Estimated completion is 2025-07-20.
What conditions does trial NCT06938815 study?
This clinical trial studies the following conditions: Post-inflammatory Hyperpigmentation.
What interventions are being tested in trial NCT06938815?
The interventions under investigation include: Pigment Balancing Peel (OTHER), Discoloration Defense Serum (OTHER), LHA Cleansing Gel (OTHER), Hydrating B5 Gel (OTHER), Daily Brightening Sunscreen (OTHER).
Who is sponsoring clinical trial NCT06938815?
This trial is sponsored by Narrows Institute for Biomedical Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06938815 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-inflammatory Hyperpigmentation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI